Foresee Genomics

Cancer Genomics Diagnostics

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in August 2017 by Arnon Chait and Roi Feingersch, Foresee Genomics operates with 1–10 employees. The company has raised $2.1M across 4 funding rounds from 3 investors. In February 2024, Foresee Genomics secured funding from GoodPaper Ventures.

Business overview

Foresee Genomics develops a DNA testing system for cancer patients, integrating molecular biology and computational analysis. Their tests provide physicians with genetic data to inform treatment options. The company's procedure utilizes low-cost equipment, enabling point-of-care diagnostics in hospitals and local clinics. Foresee Genomics operates within the Health Tech & Life Sciences sector, specifically focusing on Digital Medical Diagnostics, and serves healthcare providers in markets such as Israel, Europe, and North America.

Log in to access full profile

Company Intelligence Q&A

What is Foresee Genomics' primary focus?
Foresee Genomics is focused on developing a DNA testing system for cancer patients, combining molecular biology and computational analysis to provide genetic data for treatment decisions.
When was Foresee Genomics founded and by whom?
Foresee Genomics was founded in August 2017 by Arnon Chait and Roi Feingersch.
What type of non-equity funding did Foresee Genomics receive?
In December 2017, Foresee Genomics received a grant from the Israel Innovation Authority.
Log in to access full profile